Top scientists from have suggested that GLP-1s could have broader effects than just tackling obesity and diabetes.

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

It’s a tough time to be looking for a job. Amid wider economic uncertainty, some analysts have said that businesses are at a ...

Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...

Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without ...

Novo Nordisk's discounted valuations and promising oral candidate may trigger a drastic reversal in its stock ...

With one in eight adults taking drugs like Ozempic and Mounjaro, emerging evidence shows that the medication has potential to ...

Novartis raised its peak sales guidance for two of its biggest drugs--Kisqali for breast cancer and Scemblix for leukemia. It now forecasts Kisqali sales to top $10 billion at their peak, up from $8 ...

Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader at the nexus of serialization ...